课题基金 / 基金详情

Novel Cellular Probe Technologies for Screening Anti-Viral Therapeutic Candidates on Multiple Platforms

Novel Cellular Probe Technologies for Screening Anti-Viral Therapeutic Candidates on Multiple Platforms
用于在多个平台上筛选抗病毒治疗候选药物的新型细胞探针技术
批准号:
60344
负责人:
金额:
$9.51万
依托单位:
依托单位国家:
英国
项目类别:
Feasibility Studies
财政年份:
2020
资助国家:
英国
项目状态:
已结题
起止时间:
2020 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
新冠肺炎已经证明,新出现的病毒对人类健康构成严重威胁。在流行病迅速传播期间,受影响的个人需要紧急使用抗病毒药物和拦截组织损害的药物进行治疗。在过去的20年里,BioStatus一直在发明、开发和制造创新的试剂和分子探针,用于生物医学中基于细胞的分析、成像和筛选应用。我们为世界各地的客户提供ISO 9001:2015质量标准。作为一家创新的公司,我们寻求在我们最能服务的领域产生积极影响--在我们的情况下,新疗法的发现管道。我们的项目目标是迅速开发新的探头系列和我们现有探头的新颖组合。我们的荧光试剂经过化学设计,可以进入细胞并揭示病毒攻击带来的变化。我们的专利技术使研究人员能够探索人类细胞如何应对病毒攻击,以及新的候选药物是否可以防止病毒感染造成的损害。最终目标是提供经过筛选和验证的药物,这些药物可以阻止疾病的发展,避免长期的健康后果。
英文摘要
COVID-19 has demonstrated that emerging viruses present acute threats to human health. During rapidly spreading epidemics, affected individuals need to be treated urgently with antivirals and agents that intercept tissue damage. The epidemic has highlighted the need for rapid and effective screening of both novel and repurposed agents so that promising therapeutics can enter the path to the clinic.For the last 20 years, BioStatus has been inventing, developing and manufacturing innovative reagents and molecular probes for cell-based analysis, imaging and screening applications in biomedicine. We supply customers all over the world to the ISO 9001:2015 quality standard. As an innovative company, we seek to make a positive impact in the area that we can best serve – in our case, the discovery pipeline for new treatments.Our project aim is to rapidly exploit a new family of probes and novel combinations of our existing probes. Our fluorescent reagents are chemically designed to enter cells and reveal changes brought about by a viral attack. Our patented technologies allow researchers to explore how a human cell responds to a viral attack and whether or not a new candidate drug can prevent the damage caused by that viral infection. The ultimate goal is to deliver screened and validated drugs that can halt disease progression and avoid long-term health consequences.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Cellular & Molecular Immunology
  • 批准号:
    30824806
  • 项目类别:
    专项基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2008
  • 负责人:
    魏海明
  • 依托单位: